Jérôme Jouan

Jérôme Jouan

Auto-generated profile, based on publicly available information

Jérôme Jouan

Limoges University Hospital Center

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
JJJérôme Jouan
Jérôme Jouan
AMAlessandro Mele
Alessandro Mele
EFEmmanuelle Florens
Emmanuelle Florens
GCGilles Chatellier
Gilles Chatellier
ACAlain Carpentier
Alain Carpentier
JFJean-Noël Fabiani
Jean-Noël Fabiani

1 April 2012 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
JJJérôme Jouan
Jérôme Jouan
ABAlain Berrebi
Alain Berrebi
SCSylvain Chauvaud
Sylvain Chauvaud
PMPhilippe Menasché
Philippe Menasché
ACAlain Carpentier
Alain Carpentier
JFJean-Noël Fabiani
Jean-Noël Fabiani

1 August 2012 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
JJJérôme Jouan
Jérôme Jouan
LGLisa Golmard
Lisa Golmard
NBNadine Benhamouda
Nadine Benhamouda
NDNicolas Durrleman
Nicolas Durrleman
JGJean-Louis Golmard
Jean-Louis Golmard
PMPhilippe Menasché
Philippe Menasché

31 May 2009 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
PDF file
FPFrançoise Le Pimpec-Barthes
Françoise Le Pimpec-Barthes
MPMinh Pham
Minh Pham
JJJérome Jouan
Jérome Jouan
ABAlain Bel
Alain Bel
JFJean-Noël Fabiani
Jean-Noël Fabiani
MRMarc Riquet
Marc Riquet

1 April 2009 in The International Journal of Artificial Organs
Verified
Journal Article
Closed access
PDF file
JJJérôme Jouan
Jérôme Jouan
JGJean-Michel Grinda
Jean-Michel Grinda
MBMarie-Odile Bricourt
Marie-Odile Bricourt
LILaurence Iserin
Laurence Iserin
JFJean-Noël Fabiani
Jean-Noël Fabiani
Cardiac transplantation is an ever more frequent requirement for patients presenting with end-stage right systemic ventricular failure late after atrial switch operations. But as the time on the donor waiting list lengthens, the clinical conditions of these patients can easily and abruptly deteriorate, sometimes requiring systemic ventricular assistance. We document the first case of right systemic ventricular assistance with a De Bakey VAD axial pump in a patient presenting with systemic ventricular failure 23 years after procedure. He rapidly recovered total autonomy and was thus able to participate in a rehabilitation program to optimize his condition for heart transplantation.

26 December 2017 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
PDF file
YJYashutosh Joshi
Yashutosh Joshi
PAPaul Achouh
Paul Achouh
PMPhilippe Menasché
Philippe Menasché
JFJean-Noel Fabiani
Jean-Noel Fabiani
ABAlain Berrebi
Alain Berrebi
JJJérôme Jouan
Jérôme Jouan
Surgical mortality and long-term outcomes are important considerations when determining strategies for multiple reoperations on the aortic valve (AV). With the rise of percutaneous valve-in-valve, we sought to evaluate the current outcomes of conventional surgery for AV reoperation, focusing first on the effect of the number of previous AV interventions with a subsequent analysis of the risk factors for adverse outcomes. From January 2007 to December 2016, 316 consecutive patients underwent an open redo operation (replacement) on their AV at a single centre. It was the first AV reintervention in 263 patients (Group 1), second in 42 patients (Group 2) and third or more in 11 patients (Group 3). There were 230 men and 86 women, with a median age of 58 (Q1–Q3: 46–70) years. Structural valve deterioration (SVD) of the bioprosthesis (n = 136, 44%), endocarditis (n = 57, 18%) and prosthetic valve dehiscence (n = 41, 13%) were the most common reasons for reintervention. Overall, in-hospital mortality was 7.3%: 7.2% in Group 1, 4.76% in Group 2 and 18.2% in Group 3 (P = 0.233) and ranged from 3.7% for SVD to 14.0% when endocarditis was the reason for reintervention. Higher preoperative New York Heart Association (NYHA) class (III/IV) [odds ratio (OR) 15.9, P = 0.011], injury during re-entry (OR 16.9, P = 0.015), endocarditis (OR 3.7, P = 0.038) and concomitant mitral valve replacement (OR 5.6, P = 0.006) were independent risk factors for in-hospital mortality. Survival at 8 years was 79.0 ± 3.0% for the entire cohort and 88.4 ± 3.2% for re-replacement after SVD. Multiple AV reoperations carry an acceptable risk of early postoperative mortality, particularly for isolated valve replacements of SVD.